

**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/949,572 entitled "Free Floating Cryostat Sections for Immunoelectron Microscopy," filed September 10, 2001. Foreign rights are also available (PCT/US01/28340). The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** This invention relates to the field of histology and immuno-histology using immunoelectron microscopy. More specifically, this invention relates to the field of free-floating cryostat sections for use in light and electron microscopy to bridge the gap between these two viewing mediums.

**Luz D. Ortiz,**  
*Army Federal Register Liaison Officer.*  
[FR Doc. 02-19709 Filed 8-2-02; 8:45 am]  
**BILLING CODE 3710-08-M**

**DEPARTMENT OF DEFENSE****Department of the Army**

**Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Heterologous Protection Induced by Immunization With Invaplex Vaccine**

**AGENCY:** Department of the Army, DoD.

**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 10/150,814 entitled "Heterologous Protection Induced by Immunization with Invaplex Vaccine," filed May 17, 2002. Foreign rights (PCT/US02/16029) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** In this application is described a composition, Invaplex, derived from a gram negative bacteria for use in generating an immune response in a subject against one or more heterologous species or strains of gram-negative bacteria.

**Luz D. Ortiz,**  
*Army Federal Register Liaison Officer.*  
[FR Doc. 02-19710 Filed 8-2-02; 8:45 am]  
**BILLING CODE 3710-08-M**

**DEPARTMENT OF DEFENSE****Department of the Army**

**Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Microfluidized Leishmania Lysate and Methods of Making and Using Thereof**

**AGENCY:** Department of the Army, DOD.  
**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/975,020 entitled "Microfluidized Leishmania Lysate and Methods of Making and Using Thereof," filed October 12, 2001. Foreign rights (PCT/US01/31894) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** This invention relates generally to microfluidized *Leishmania* lysate

preparations. In particular, the present invention relates to microfluidized *Leishmania* lysate preparations for assays and immunogenic compositions.

**Luz D. Ortiz,**  
*Army Federal Register Liaison Officer.*  
[FR Doc. 02-19715 Filed 8-2-02; 8:45 am]  
**BILLING CODE 3710-08-M**

**DEPARTMENT OF DEFENSE****Department of the Army**

**Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins**

**AGENCY:** Department of the Army, DOD.  
**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the related U.S. patent applications concerning "Specific Inhibitors and therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins" listed below. The United States Government, as represented by the Secretary of the Army, has rights in these inventions. Foreign rights are also available.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 1702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, bh at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** The following patents are available for licensing:

(1) *U.S. Patent Application No.:* 09/570,022.  
*Filed:* May 12, 2000.

*Title:* Previns as Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins.

*Supplementary Information:* The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

(2) *U.S. Patent Application No.:* 09/570,023.  
*Filed:* May 12, 2000.